Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA

Financial Enhancement Group LLC acquired a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 32,819 shares of the company’s stock, valued at approximately $631,000. Financial Enhancement Group LLC owned 0.09% of Oruka Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Braidwell LP lifted its holdings in shares of Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock valued at $16,133,000 after buying an additional 424,750 shares during the period. Geode Capital Management LLC increased its position in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after acquiring an additional 354,821 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Oruka Therapeutics by 40.6% in the second quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock valued at $11,355,000 after acquiring an additional 292,421 shares during the period. Goldman Sachs Group Inc. bought a new position in Oruka Therapeutics in the first quarter valued at about $2,505,000. Finally, Affinity Asset Advisors LLC boosted its position in Oruka Therapeutics by 47.9% in the first quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock worth $5,595,000 after purchasing an additional 176,664 shares during the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. BTIG Research boosted their target price on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They set a “buy” rating and a $45.00 target price for the company. HC Wainwright dropped their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Finally, Barclays started coverage on Oruka Therapeutics in a report on Monday, October 13th. They issued an “overweight” rating and a $48.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.88.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00. Following the completion of the sale, the insider directly owned 1,518 shares of the company’s stock, valued at $46,465.98. This trade represents a 82.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 24.69% of the stock is owned by insiders.

Oruka Therapeutics Stock Performance

ORKA opened at $31.84 on Friday. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -16.76 and a beta of -0.41. The firm’s fifty day moving average is $28.46 and its 200 day moving average is $19.52. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $32.28.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.